FY2025 EPS Estimates for Tilray Lifted by Atb Cap Markets

Tilray Inc (NASDAQ:TLRY) – Investment analysts at Atb Cap Markets increased their FY2025 earnings per share (EPS) estimates for Tilray in a research note issued on Monday, December 16th. Atb Cap Markets analyst F. Gomes now expects that the company will post earnings of ($0.13) per share for the year, up from their previous forecast of ($0.14). The consensus estimate for Tilray’s current full-year earnings is ($0.14) per share. Atb Cap Markets also issued estimates for Tilray’s FY2026 earnings at ($0.11) EPS, FY2027 earnings at ($0.04) EPS and FY2029 earnings at $0.05 EPS.

Tilray (NASDAQ:TLRY) last posted its earnings results on Thursday, October 10th. The company reported ($0.04) EPS for the quarter, hitting analysts’ consensus estimates of ($0.04). The business had revenue of $200.00 million for the quarter, compared to analysts’ expectations of $218.70 million. Tilray had a negative return on equity of 2.00% and a negative net margin of 26.79%. The business’s revenue was up 13.0% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.10) earnings per share.

Separately, Roth Mkm lowered their target price on Tilray from $2.00 to $1.75 and set a “neutral” rating on the stock in a research note on Friday, October 11th.

Tilray Stock Up 8.6 %

Shares of NASDAQ:TLRY opened at $1.26 on Thursday. The firm has a fifty day moving average price of $1.44 and a 200 day moving average price of $1.65. Tilray has a 1-year low of $1.14 and a 1-year high of $2.97. The company has a debt-to-equity ratio of 0.08, a current ratio of 2.47 and a quick ratio of 1.57. The stock has a market cap of $1.14 billion, a P/E ratio of -4.67 and a beta of 2.08.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Ferguson Wellman Capital Management Inc. purchased a new stake in shares of Tilray in the third quarter valued at about $26,000. Signature Estate & Investment Advisors LLC purchased a new position in shares of Tilray during the second quarter valued at approximately $29,000. Jeppson Wealth Management LLC acquired a new position in Tilray in the 2nd quarter valued at $33,000. Vanguard Capital Wealth Advisors purchased a new position in shares of Tilray during the 2nd quarter worth $34,000. Finally, Pallas Capital Advisors LLC purchased a new stake in shares of Tilray in the second quarter valued at $37,000. Institutional investors and hedge funds own 9.35% of the company’s stock.

Insider Buying and Selling at Tilray

In other news, CFO Carl A. Merton acquired 26,000 shares of Tilray stock in a transaction that occurred on Friday, November 15th. The stock was purchased at an average cost of $1.36 per share, with a total value of $35,360.00. Following the completion of the acquisition, the chief financial officer now owns 26,000 shares in the company, valued at $35,360. This trade represents a ? increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. 0.87% of the stock is currently owned by corporate insiders.

About Tilray

Tilray, Inc engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc is headquartered in Canada.